Evaluation of Insulin Infusion Rates for the Treatment of Diabetic Ketoacidosis in the Emergency Department.

Diabetic Ketoacidosis Dose Infusion Rates Intravenous Insulin Regular Insulin

Journal

Journal of biosciences and medicines
ISSN: 2327-5081
Titre abrégé: J Biosci Med (Irvine)
Pays: United States
ID NLM: 101686921

Informations de publication

Date de publication:
Mar 2022
Historique:
entrez: 7 4 2022
pubmed: 8 4 2022
medline: 8 4 2022
Statut: ppublish

Résumé

There is minimal literature to support the appropriate dosing for the initiation of IV regular insulin therapy in DKA patients. A 0.1 unit/kg bolus followed by 0.1 units/kg/hour or 0.14 units/kg/hour is commonly utilized and recommended in guidelines. We sought to assess clinical and safety outcomes associated with various insulin infusion starting doses in patients diagnosed with DKA in the emergency department in an effort to help guide prescribing. A retrospective cohort study was conducted within an academic emergency department and included patients who received continuous infusion regular insulin with an ICD-10 code for DKA between January 2016 and January 2019. A predictive regression model was applied to test if predefined lab values influenced the starting insulin infusion rates. Clinical and safety outcomes were evaluated by starting insulin infusion rate. Data was analyzed based on starting insulin infusion rates. 347 patients met inclusion criteria with 92 (26.5%) patients receiving <0.07 units/kg/hr, 123 (35.4%) patients receiving 0.07 to 0.099 units/kg/hr, 123 (35.4%) patients receiving 0.10 to 0.139 units/kg/hr, and 9 (2.6%) patients receiving ≥0.14 units/kg/hr. After adjusting for baseline labs, glucose was the only significant predictor of the initial infusion rate (p < 0.001). For every 100 mg/dL increase in the baseline glucose value, the initial infusion rate increased by 0.005 units/kg/hr. There was no difference between insulin starting infusion rates and length of stay, rates of hypoglycemia, hypokalemia, or dysrhythmias. Glucose levels significantly influenced the insulin starting infusion rate, with no identified differences in adverse effects or clinical outcomes.

Identifiants

pubmed: 35386489
doi: 10.4236/jbm.2022.103019
pmc: PMC8983016
mid: NIHMS1792265
doi:

Types de publication

Journal Article

Langues

eng

Pagination

203-211

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR002535
Pays : United States

Déclaration de conflit d'intérêts

Conflicts of Interest The authors report no conflicts of interest related to this work.

Références

N Engl J Med. 1977 Aug 4;297(5):238-41
pubmed: 406561
Diabetes Care. 2008 Nov;31(11):2081-5
pubmed: 18694978
J Clin Endocrinol Metab. 2008 May;93(5):1541-52
pubmed: 18270259
Diabet Med. 2016 Feb;33(2):252-60
pubmed: 26286235
Diabetes Care. 2001 Jan;24(1):131-53
pubmed: 11194218
J Clin Diagn Res. 2015 May;9(5):OC01-5
pubmed: 26155506
J Emerg Med. 2010 May;38(4):422-7
pubmed: 18514472
J Endocr Soc. 2019 Apr 11;3(5):1079-1086
pubmed: 31069278
J Clin Endocrinol Metab. 2012 Sep;97(9):3132-7
pubmed: 22685233
Diabetes Care. 2009 Jul;32(7):1335-43
pubmed: 19564476
Acad Emerg Med. 2015 Jun;22(6):657-62
pubmed: 26013711
Curr Diab Rep. 2017 May;17(5):33
pubmed: 28364357
J Thromb Thrombolysis. 2021 Aug;52(2):517-522
pubmed: 33420896
Diabetes Care. 2004 Jan;27 Suppl 1:S94-102
pubmed: 14693938

Auteurs

Megan E Bass (ME)

Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.

Nicole Paavola (N)

Department of Pharmacy, UCHealth, University of Colorado Hospital, Aurora, CO, USA.

Tyree H Kiser (TH)

Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.

Garth Wright (G)

Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.

Gabrielle Jacknin (G)

Department of Pharmacy, UCHealth, University of Colorado Hospital, Aurora, CO, USA.

Classifications MeSH